Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

6.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.560
Bid (Size) 5.660 (200)
Ask (Size) 6.950 (1,000)
Prev. Close 6.560
Today's Range 6.560 - 6.560
52wk Range 0.9807 - 6.830
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
Which stocks are gapping on Tuesday? ↗
Via Chartmill

Performance

YTD
+140.3%
+140.3%
1 Month
+68.6%
+68.6%
3 Month
+57.7%
+57.7%
6 Month
+99.4%
+99.4%
1 Year
+437.7%
+437.7%

More News

Read More
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension ↗
Via Chartmill
News headline image
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
From Equity Insider
Via GlobeNewswire
News headline image
Why Did PRLD Stock Surge 13% Today? ↗
Via Stocktwits
News headline image
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
Via Chartmill
News headline image
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill

Frequently Asked Questions

Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
What is the current price of Prelude Therapeutics Incorporated - Common Stock?
The current price of Prelude Therapeutics Incorporated - Common Stock is 6.560
When was Prelude Therapeutics Incorporated - Common Stock last traded?
The last trade of Prelude Therapeutics Incorporated - Common Stock was at 08/26/26 04:00 PM ET
What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 359.55M
How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
Prelude Therapeutics Incorporated - Common Stock has 360M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.